Literature DB >> 11745230

Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study.

M Koda1, Y Murawaki, A Mitsuda, K Oyama, K Okamoto, Y Idobe, T Suou, H Kawasaki.   

Abstract

BACKGROUND: To assess whether the effectiveness of a combination of transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) is superior to PEI alone in the treatment of patients with small hepatocellular carcinoma (HCC), a randomized controlled study was performed.
METHODS: Fifty-two patients with one to three HCC tumors measuring < than 3 cm in greatest dimension were enrolled and underwent the combination TACE-PEI therapy (26 patients with 31 nodules) or PEI alone (26 patients with 34 nodules). There were no significant differences in background between the two groups. The mean follow-up was 30.1 months +/- 17.5 months.
RESULTS: The cumulative detection rates of local residual disease in the TACE-PEI group (3.7% at 1 year and 19.3% at 3 years) were significantly lower compared with the detection rates in the PEI alone group (34.2% and 39.3%, respectively; P = 0.013). The cumulative new nodular recurrence rates in the TACE-PEI group (8.7% at 1 year and 19.3% at 3 years) tended to be lower compared with the recurrence rates in the PEI alone group (26.9% and 80.1%, respectively; P = 0.057). The cumulative survival rates were not significantly different between the two groups (TACE-PEI group: 100%, 80.8%, and 40.4% at 1 year, 3 years, and 5 years, respectively; PEI alone group: 91.3%, 65.9%, and 37.7%, respectively; P = 0.458). However, among the patients from each group with HCC tumors measuring < 2 cm, the survival rates in the TACE-PEI group were improved compared with the survival rates in the PEI alone group (P < 0.01) in addition to the detection rates of local residual disease and the new nodular recurrence rates (P < 0.01 and P = 0.047, respectively). The frequency of short-term and long-term adverse effects was not significantly different between the groups. However, only two major complications (biloma and ascites with pleural effusion) were observed, both of which occurred in patients in the TACE-PEI group.
CONCLUSIONS: Combination therapy with TACE-PEI was superior to PEI alone in the treatment of patients with small HCC tumors, especially for patients with HCC tumors measuring < 2 cm in greatest dimension. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745230     DOI: 10.1002/1097-0142(20010915)92:6<1516::aid-cncr1477>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  43 in total

Review 1.  Treatment of hepatocarcinoma.

Authors:  Beatrice Gerard; Harry Bleiberg
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

2.  Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.

Authors:  Sonja K Olsen; Robert S Brown; Abby B Siegel
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

Review 3.  Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis.

Authors:  Lili Gu; Huiling Liu; Linlin Fan; Yuanjun Lv; Zhuang Cui; Yan Luo; Yuanyuan Liu; Guang Li; Changping Li; Jun Ma
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

4.  The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy.

Authors:  Mitchell T Smith; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

5.  Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma.

Authors:  Do Seon Song; Soon Woo Nam; Si Hyun Bae; Jin Dong Kim; Jeong Won Jang; Myeong Jun Song; Sung Won Lee; Hee Yeon Kim; Young Joon Lee; Ho Jong Chun; Young Kyoung You; Jong Young Choi; Seung Kew Yoon
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 6.  Combined interventional therapies of hepatocellular carcinoma.

Authors:  Jun Qian; Gan-Sheng Feng; Thomas Vogl
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 7.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

8.  Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE.

Authors:  Fu-Hua Yan; Kang-Rong Zhou; Jie-Min Cheng; Jian-Hua Wang; Zhi-Ping Yan; Reng-Rong Da; Jia Fan; Yuan Ji
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

9.  Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.

Authors:  Wei-Jian Guo; Er-Xin Yu; Lu-Ming Liu; Jie Li; Zhen Chen; Jun-Hua Lin; Zhi-Qiang Meng; Yi Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  Addition of transcatheter arterial chemoembolization decreased local recurrence but had no survival benefit to percutaneous ethanol injection therapy for patients with small hepatocellular carcinoma: A multicenter randomized control study.

Authors:  Akira Mizuki; Masayuki Tatemichi; Nobuhiro Tsukada; Ryousuke Nagamatsu; Mitsuhiko Kawaguchi; Tatsuya Itoshima; Shigeki Maruyama; Atsuhiko Satou; Yasuhisa Imari; Toshiharu Kawatoko; Junya Shimono; Hiroshi Nagata
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.